FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 359:2725-2726 December 18, 2008 Number 25 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Vermorken, J. B. PubMed Citation

To the Editor: The study of chemotherapy plus cetuximab in patients with head and neck cancer, reported by Vermorken et al. (Sept. 11 issue),¹ is limited by the fact that enrollment was restricted to patients with a good Karnofsky performance score (70 or more). The subgroup analysis indicated that patients with a Karnofsky performance score between 70 and 80 did not benefit from treatment with cetuximab. Many patients with recurrent squamous-cell carcinoma of the head and neck present with a much worse performance status than those enrolled in the study by Vermorken et al.² Therefore, whether the addition of cetuximab . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.